BeStock  
Stocks › Biotechnology › HALO

Halozyme Therapeutics HALO

US equityMarket cap rank #1380Biotechnology
$91.35 −$1.69 (-1.82%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $91.35 0.00%
Open$93.64
Prev close$93.04
Day range$90.79 – $93.64
Volume1.50M
Market cap$10.41B
P/E (TTM)22.8
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership114.0%-0.20 pts vs. prior quarter
Institutions holding912-4 vs. prior quarter
Insider trades (recent)26 buys / 24 sellsNet buying
Short interest12.03% of floatDays to cover 6.8 · as of 30 Oct 2026
Short-sale volume share9.7%5-day average of daily volume

Short-sale volume as % of daily volume

5%12%18%25%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$17.23M (9 inflow days, 11 outflow days).

Net flow by order size, last 20 sessions

−$14.2MSuper−$3.0MBig+$354.1KMid+$19.9MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 29.0% of shares outstanding.

Largest holders

  • BlackRock11.99%
  • Vanguard Capital Management, LLC5.12%
  • State Street Global Advisors4.44%
  • Vanguard Portfolio Management, LLC4.37%
  • Two Sigma Investments, LP3.09%
  • D. E. Shaw & Co., L.P.2.96%
  • Invesco Ltd.2.58%
  • William Blair Investment Management, LLC2.28%

By investor type

  • Mutual Fund86.27%
  • Hedge Fund11.64%
  • Public Company7.63%
  • Private Company3.56%
  • Government Pension Fund2.46%
  • Sovereign Wealth Fund1.30%
  • Individual/Insider1.05%
  • Family Office/Trust0.63%

Reported short interest has fallen from 12.90% to 12.03% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Distillate Capital Partners LLC Mutual Fund 2026/Q3 +149,323 0.1%
Two Sigma Investments, LP Hedge Fund 2026/Q4 +1,865,872 3.1%
D. E. Shaw & Co., L.P. Hedge Fund 2026/Q4 +1,367,027 3.0%
Congress Asset Management Company, LLP Mutual Fund 2026/Q4 +1,052,509 2.0%
Wasatch Advisors LP Mutual Fund 2026/Q4 +1,049,647 0.9%
Neuberger Berman Investment Advisers LLC Mutual Fund 2026/Q4 +939,064 1.1%
Frontier Capital Management Mutual Fund 2026/Q4 +852,151 1.0%
Jane Street Group, LLC Private Company 2026/Q4 +823,999 1.3%
Marshall Wace LLP Hedge Fund 2026/Q4 +552,920 0.7%
First Trust Advisors L.P. Mutual Fund 2026/Q4 +400,761 1.6%
BlackRock Mutual Fund 2026/Q4 +397,471 12.0%
Hudson River Trading LLC Private Company 2026/Q4 +330,187 0.6%
FMR Mutual Fund 2026/Q4 +328,841 0.3%
UBS Asset Management Mutual Fund 2026/Q4 +324,746 1.9%
Invesco Ltd. Mutual Fund 2026/Q4 +315,227 2.6%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
7 Oct 2026 Helen Torley Chief Executive Officer Derivative Exercise and Sale -60,000 $113.69 767,780
30 Sep 2026 James Daly Director Other Acquisition +1,169 – 1,169
30 Sep 2026 James Daly Director Other Derivative Acquisition +1,775 $106.94 1,775
30 Sep 2026 Matthew Posard Independent Director Automatic Disposition -5,230 $110.04 49,813
15 Sep 2026 Matthew Posard Independent Director Automatic Disposition -18,996 $108.99 55,043
10 Sep 2026 Helen Torley Chief Executive Officer Derivative Exercise and Sale -60,000 $108.67 767,780
31 Aug 2026 Dannielle Appelhans Director Other Acquisition +1,161 – 1,161
31 Aug 2026 Dannielle Appelhans Director Other Derivative Acquisition +1,778 $107.72 1,778
18 Aug 2026 Helen Torley Chief Executive Officer Derivative Exercise and Sale -60,000 $107.77 767,780
9 Aug 2026 Bernadette Connaughton Independent Director Automatic Disposition -1,626 $102.80 33,622
7 Jul 2026 Helen Torley Chief Executive Officer Derivative Exercise and Sale -1,923 $80.19 767,780
30 Jun 2026 David Ramsay President of Drug Delivery Other Derivative Acquisition +16,232 – 16,232
30 Jun 2026 David Ramsay President of Drug Delivery Other Derivative Acquisition +39,823 $77.01 39,823
30 Jun 2026 Bernadette Connaughton Independent Director Automatic Disposition -1,625 $77.21 35,248
30 Jun 2026 Darren Snellgrove Senior Vice President Other Derivative Acquisition +41,554 – 41,554
30 Jun 2026 Darren Snellgrove Senior Vice President Other Derivative Acquisition +127,432 $77.01 127,432
29 Jun 2026 David Ramsay President of Drug Delivery Derivative Exercise and Sale -5,408 $78.27 4,592
29 Jun 2026 David Ramsay President of Drug Delivery Derivative Exercise and Retained +4,592 – 4,592
28 Jun 2026 Mahesh Krishnan Independent Director Derivative Exercise and Sale -7,304 $75.00 10,666
11 Jun 2026 Mark Snyder Executive VP, General Counsel, Chief Compliance Officer & Corporate Secretary Derivative Exercise and Sale -2,715 $69.50 49,929

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 13,650,219 12.0% 6.8
15 Oct 2026 13,654,228 12.0% 6.2
30 Sep 2026 15,295,841 13.5% 4.5
15 Sep 2026 15,154,414 13.4% 11.6
31 Aug 2026 14,880,707 13.1% 8.7
14 Aug 2026 14,636,927 12.9% 5.0

Discussion

No comments yet — be the first to weigh in on HALO.

Sign in to join the discussion.

Scroll to Top